CORT Corcept Therapeutics Incorporated
Company Analysis
Latest News
Corcept Therapeutics Gains Support as ADA and EASD Recommend Hypercortisolism Screening
A new consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommends screening patients...
🔴 Corcept Therapeutics is trading 4.25% down in pre-market
Corcept Therapeutics is trading at $111.50, down -4.25% before the October 21, 2026 session; no clear catalyst has been identified. - The price compares with...
🟢 Corcept Therapeutics is trading 4.17% up today amid biotech-sector gains
Corcept Therapeutics is trading at $116.77, up 4.17%, amid biotech-sector strength. - No clear company-specific announcement dated October 20, 2026, emerged...
🔴 Corcept Therapeutics is trading 4.05% down today as biotech and broader markets decline
Corcept Therapeutics is trading 4.05% lower at $108.78 on October 16, 2026, amid pressure on risk-sensitive stocks as biotech and broader markets decline. -...
🔴 Corcept Therapeutics is trading 4.3% down today with biotech weakness a possible factor
Corcept Therapeutics is trading 4.3% down at $116.80, with biotechnology-sector weakness a possible contributor. - No clear company-specific announcement or...
🟢 Corcept Therapeutics is trading 4.19% up — no clear company-specific catalyst
Corcept Therapeutics is trading at $121.11, up 4.19%, with no clear company-specific catalyst identified for the October 5 move. - Its latest listed releases...
🔴 Corcept Therapeutics is trading 11.34% down in pre-market
Corcept Therapeutics is trading at $101.09, down 11.34% in pre-market, with no company announcement identified to explain the decline. - The company’s latest...
🔴 Corcept Therapeutics is trading 5.87% down in pre-market
Corcept Therapeutics is trading at $109.28, down 5.87% in pre-market, with no clear company-specific announcement identified to explain the decline. - The...
🟢 Corcept Therapeutics is trading 4.09% up today after CHMP recommends relacorilant approval
Corcept Therapeutics is trading 4.09% up now at $117.56 after the EMA’s CHMP recommended European approval of relacorilant with nab-paclitaxel for...
🔴 Corcept Therapeutics is trading 4.17% down today as rising Treasury yields pressured growth-oriented healthcare shares
Corcept Therapeutics is trading at $112.61, down 4.17%, as broader risk-off trading pressured biotech shares. - No credible company-specific negative...
🔴 Corcept Therapeutics is trading 72.64% down in after-hours trading with no credible company-specific explanation
Corcept Therapeutics is trading at $32.15, down 72.64% after hours after a $117.50 close on September 22, 2026; no credible company-specific explanation was...
🟢 Corcept Therapeutics is trading 4.16% up today amid broader biotech strength
Corcept Therapeutics is trading 4.16% up at $118.49, supported primarily by broader biotechnology strength rather than a newly announced company-specific...
🟢 Corcept Therapeutics is trading 4.12% up today as risk-on sentiment strengthens
Corcept Therapeutics is trading at $114.83 (+4.12%) on September 21, 2026, amid a stronger risk-on market. - The S&P 500 is up 1.00% and Nasdaq is up 1.50%. -...
🔴 Corcept Therapeutics is trading 4.5% down today — no specific bearish catalyst identified
Corcept Therapeutics is trading 4.5% down at $109.71 despite favorable developments; no reliable source identified a specific bearish catalyst. -...
🔴 Corcept Therapeutics is trading 4.12% down in pre-market; immediate catalyst remains unclear
Corcept Therapeutics is trading 4.12% down in pre-market at $106.25, with the immediate catalyst unclear. - It fell from the September 15 close of $110.82; no...
🔴 Corcept Therapeutics is trading 4.01% down today — no clear catalyst identified
Corcept Therapeutics is trading 4.01% down at $110.31, with no clear company-specific catalyst identified. - No clear company-specific announcement, filing,...
Perceptive Advisors Boosts Stake in Corcept Therapeutics by Nearly 700%
Healthcare-focused investment firm Perceptive Advisors significantly increased its position in Corcept Therapeutics (CORT) during the second quarter of 2026,...
🔴 Corcept Therapeutics is trading 4.6% down today on profit-taking after last week’s 27% post-earnings surge
Corcept Therapeutics is trading 4.6% down at $109.25 as investors take profits following a sharp rally driven by a recent earnings beat and a major revenue...
🟢 Corcept Therapeutics is trading 4.8% up today after raising its full-year revenue guidance and reporting strong earnings
Corcept Therapeutics is trading at $119.99 (+4.80%) in pre-market following its July 29 earnings report, which highlighted strong launch momentum for Lifyorli...
🟢 Corcept Therapeutics is trading 5.7% up today after a strong Q2 earnings beat and guidance hike
Corcept Therapeutics is trading 5.7% up at $121.00 in after-hours trading, extending a sharp rally following its Q2 2026 financial results. • The company...